Search results
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic...
Simply Wall St. via Yahoo Finance· 1 month agoKey Insights Using the 2 Stage Free Cash Flow to Equity, Arrowhead Pharmaceuticals fair value...
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Insider Monkey via Yahoo Finance· 11 months agoBaron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter...
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR)...
Simply Wall St. via Yahoo Finance· 3 days agoKey Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock...
Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something...
Simply Wall St. via Yahoo Finance· 2 years agoThe big shareholder groups in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have power over the...
Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease
Investor's Business Daily· 11 months agoArrowhead Pharmaceuticals said Thursday a single dose of its experimental drug almost completely...
Great week for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) institutional investors after losing...
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Institutions' substantial holdings in Arrowhead Pharmaceuticals implies that they have...
Baron Funds: “We Retain Conviction in Arrowhead (ARWR)”
Insider Monkey via Yahoo Finance· 2 years agoBaron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022...
After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last...
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock...
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
Investor's Business Daily· 1 year agoArrowhead Pharmaceuticals has provided a bullish update for its midstage liver disease treatment,...
Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 982%...
Simply Wall St. via Yahoo Finance· 2 years agoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders have seen the share price descend 19%...